Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $205.96 | Prev. Close $205.27 | Circuit Range N/A |
Day Range $205.27 - $208.24 | Year Range $122.80 - $212.19 | Volume 17,273 |
Average Traded $207.47 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $205.96 | $205.27 | +0.00% |
12-Nov-25 | $205.96 | $205.27 | +1.06% |
11-Nov-25 | $202.88 | $203.12 | +1.90% |
10-Nov-25 | $201.13 | $199.32 | +0.66% |
07-Nov-25 | $198.13 | $198.01 | -0.84% |
06-Nov-25 | $199.00 | $199.69 | -0.09% |
05-Nov-25 | $199.49 | $199.85 | -1.63% |